Aurinia Pharmaceuticals (TSE:AUP) (NASDAQ:AUPH) will be announcing its earnings results after the market closes on Thursday, March 15th. Analysts expect the company to announce earnings of C($0.18) per share for the quarter.
Shares of Aurinia Pharmaceuticals (AUP) opened at C$6.90 on Thursday. The firm has a market capitalization of $572.39, a PE ratio of -4.06 and a beta of 3.34. Aurinia Pharmaceuticals has a 12-month low of C$5.68 and a 12-month high of C$14.17.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.